Xeris Biopharma reports Q3 EPS (9c), consensus (12c)

Reports Q3 revenue $48.32M, consensus $41.08M. “We continue to demonstrate record revenue growth as we execute on our strategy. Because of this strong performance, we are further tightening our full year 2023 revenue guidance from $155 million – $165 million to $160 million – $165 million, which is at the high end of our original range,” said Paul R. Edick, Chairman and CEO of Xeris Biopharma. “Due to continued disciplined expense management coupled with our strong revenue growth we are confident we will achieve cash flow breakeven in the fourth quarter.”